Global sales of new so-called miracle drugs to counter obesity could expand from $10 billion to $100 billion by 2030, according to investment bank Goldman Sachs. The treatments, which include Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, work by regulating appetites, including by slowing the stomach-emptying process and signalling to the brain that there is food in the gut. Appetite for the drugs could grow beyond those projections, particularly if the health insurance industry develops a taste for including them in policies. According to Goldman Sachs, “the drugs are expensive, insurance co…